NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $739,000, down 17 percent from $888,000 in the first quarter of 2013.

Sales of the company's BGM-Galectin-3 heart failure test accounted for all of its revenues. It posted no service revenues in the quarter, compared to $68,000 in service revenues in Q1 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.